Developer docs
API playgroundTry for free, no card

Search company profiles

Synapse Medicine

Full company profile

uuid0000d73

Namestring
Synapse Medicine
Legal namestring
Synapse Medicine
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Synapse Medicine is a French healthtech company founded in 2017 that builds an AI-powered medication intelligence platform for healthcare professionals and software vendors. Headquartered in Bordeaux with offices in Paris, New York, and coworking locations in Lacanau and Montalivet, the company develops a knowledge-graph-architecture platform that aggregates heterogeneous drug data from official sources, including the 40-year-old Thériaque certified drug database. Its product portfolio includes Synapse Database (multi-source drug information), Synapse Secure (CE Class IIb-certified prescription safety), Synapse Copilote (an AI suite with voice, clinical follow-up, and prescription optimization modules), Synapse Prescribe (ONC-certified for the US market), and sub-brands MedGPT.fr (a generative AI medical assistant used by 150,000+ doctors in France) and Goodmed (a patient-facing app).

The underlying technology combines a proprietary knowledge graph and Synapse ontology with internally developed NLP, OCR, and recommendation algorithms, and uses Mistral LLMs for generative AI features. The platform is delivered as APIs and React Native front-end components that integrate into EHR, e-prescribing, and telehealth software, with 60+ vendor integrations completed and 400,000+ healthcare professionals reached across France, the US, Europe, and Asia. Synapse Medicine holds CE Class IIb, ISO 13485, ONC Certified Health IT, and HAS LAP/LAD certifications.

Synapse Medicine operates a B2B subscription revenue model combining direct enterprise sales to hospitals and large healthcare organizations with OEM/embedded licensing of APIs and React Native components to healthcare software vendors. Pricing is quote-based and not publicly disclosed. The go-to-market motion pairs enterprise field sales (particularly for large hospital systems and EHR publishers) with an API-first, developer-friendly integration approach. The company has raised approximately €35-40M across three funding rounds (seed 2019, Series A 2020, Series B 2022 led by Korelya Capital), with investors including XAnge, BNP Paribas Développement, MACSF, and Mutuelles Impact.

Short descriptiontext

Synapse Medicine builds an AI-powered medication intelligence platform delivered via APIs and React Native components to EHR, e-prescribing, and telehealth software vendors, as well as directly to hospitals. The platform serves 400,000+ healthcare professionals and 150,000+ doctors via MedGPT.fr across France, the US, Europe, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBordeaux, France
HQ citystring
Bordeaux
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical decision support, medication intelligence, prescription safety software, healthcare API integration, electronic prescribing platform
Industry1 code
PRIMARYHLACAKAG
Specialty Pharmacy & Complex Therapy Management Platforms
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
Clinical Decision Support Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1API and Component Licensing
TypeSubscription Recurring
Description

Revenue generated from licensing clinical decision support APIs and customizable React Native components to healthcare software vendors (EHR, e-prescribing platforms). Software publishers integrate Synapse widgets and pay for usage based on API calls or component deployments.

synapse-medicine.com
2Enterprise Software Subscriptions
TypeSubscription Recurring
Description

Direct sales to hospitals and healthcare organizations for prescription safety solutions. Complete suite of clinical decision support APIs and customizable front-end components.

careers.synapse-medicine.com
3Synapse Database
TypeSubscription Recurring
Description

Multi-source reliable drug database providing coverage of health products for international expansion

synapse-medicine.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Pricing details1 tier
1Enterprise deployment with full API access and component suite
ModelSubscriptionBilling cadenceAnnual
Notes

Pricing not publicly disclosed - requires contact with sales team for custom quotes based on deployment scope and usage

synapse-medicine.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1MedGPT
Description

Generative AI medical assistant for healthcare professionals, the first French medical AI dedicated to healthcare professionals, available at medgpt.fr

synapse-medicine.com
+1 more record
Core offering1 text field

Synapse Medicine develops a medication intelligence platform that provides clinical decision support APIs and React Native components for healthcare software vendors and providers. The platform aggregates official drug databases and uses AI to power prescription safety, drug interaction analysis, dosage verification, and personalized clinical recommendations. It is delivered as embeddable software integrated into EHR and e-prescribing systems, certified as a CE Class IIb medical device in Europe and ONC Certified Health IT in the US.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 400,000+ healthcare professionals using the platform
+4 more records
Product overview1 text field

Synapse Medicine offers a modular medication intelligence platform composed of three core products: Synapse Database (multi-source drug information), Synapse Secure (prescription safety with CE Class IIb medical device certification), and Synapse Copilote (AI-powered clinical decision support suite including voice assistant, prescription optimizer, and clinical follow-up tools). The platform is available as APIs and React Native components for EHR integration, serving over 400,000 healthcare professionals across France, the US, Europe, and Asia. Key sub-brands include MedGPT.fr (generative AI for 150,000+ doctors) and Goodmed (patient-facing app). The company also offers numerous clinical widgets (dosage analysis, drug interactions, adverse effects, pathology/allergy search, geriatric recommendations) and a pharmacovigilance module (Medication Shield), all integrated via a unified API architecture.

Product and service1 record
1Synapse Copilote
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierKey PartnerTypeTechnology or Integration
Description

Integration of Synapse Medicine's clinical decision support into CGM's e-prescribing software for European market. CGM is a major healthcare software provider.

Strategic tierIntegration PartnerTypeTechnology or Integration
Description

API and component integration into Hellocare telehealth platform to enable safer prescribing within their solution.

Strategic tierIntegration PartnerTypeTechnology or Integration
Description

Partnership extending interoperability to medication reconciliation and medication management on the Lifen Platform for improved patient care.

Strategic tierCore Data PartnerTypeTechnology or Integration
Description

40-year-old certified drug database, one of 5 databases approved by HAS (French health authority). Thériaque provides the foundational drug information for Synapse's platform.

Strategic tierGovernment PartnerTypeTechnology or Integration
Description

French medicines agency partnership for automatic annotation of adverse event reports during COVID-19 vaccination campaign. Module analyzing daily patient treatment reports.

Strategic tierResearch PartnerTypeStrategic or Co-development Partner
Description

Healthcare research partnership for trusted drug information access initiatives.

Strategic tierClinical PartnerTypeStrategic or Co-development Partner
Description

Major French cancer center partnership for medication intelligence platform deployment.

Strategic tierResearch PartnerTypeStrategic or Co-development Partner
Description

Academic partnership for healthcare innovation research collaboration.

Strategic tierResearch PartnerTypeStrategic or Co-development Partner
Description

Academic research partnership for healthcare technology innovation.

10Tokyo Metropolitan Government
Strategic tierGovernment PartnerTypeStrategic or Co-development Partner
Description

Partnership for drug information platform deployment in Japan, supporting international expansion.

synapse-medicine.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Wolters Kluwer is a large incumbent in drug information and clinical decision support, with Lexicomp and Medi-Span providing the same core capabilities as Synapse Medicine (drug interaction checking, dosage analysis, monographs) sold into hospitals, EHR vendors, and pharmacies. Comparable because it competes head-to-head in medication-decision support at enterprise scale.

2Elsevier (ClinicalKey / Gold Standard Drug Database)
TypeBroad incumbent
Description

Elsevier's Clinical Pharmacology and Gold Standard Drug Database compete directly with Synapse Database and Synapse Secure, providing drug monographs, interaction analysis, and clinical decision support to hospitals and EHR platforms. Comparable as an established content-and-CDS vendor with broad hospital penetration.

TypeDirect peer
Description

First Databank provides drug knowledge bases and clinical decision support modules embedded in EHRs and pharmacy systems, including medication screening, interaction checking, and dosing guidance - the same product surface area as Synapse Secure and Synapse Copilote. Highly comparable as a specialized CDS content and software vendor.

TypeDirect peer
Description

DrFirst delivers e-prescribing, medication management, and clinical decision support APIs to hospitals and EHR vendors, with similar OEM/embedded distribution model as Synapse Medicine. Comparable in both product scope and go-to-market approach targeting healthcare software publishers.

5RxRevu (CoverMyMeds)
TypeDirect peer
Description

RxRevu, now part of CoverMyMeds/McKesson, provides prescription decision support and real-time benefit check APIs integrated into EHR workflows - directly comparable to Synapse Prescribe and Synapse Copilote for medication decision support at the point of prescribing.

TypeBroad incumbent
Description

Epic's Best Care Alert and embedded CDS modules include medication interaction and dosing alerts that compete with Synapse's offering for hospitals running Epic. While Epic is primarily an EHR vendor, its native CDS capabilities are a direct substitute and a channel consideration for Synapse's OEM strategy.

TypeDirect peer
Description

CGM is both a partner and a comparable peer: it is a leading e-prescribing and practice management software vendor in Europe that has integrated Synapse's CDS but also operates its own clinical decision capabilities. Comparable as an e-prescribing/medication software vendor with hospital and physician footprint in Europe.

TypeEmerging player
Description

HelloCare is a telehealth platform that has integrated Synapse Medicine's API and components for safer prescribing. While smaller and more regionally focused, it is comparable as a clinical-software customer/partnership case study in the same digital health segment.

TypeBroad incumbent
Description

UpToDate is a leading evidence-based clinical decision support resource used by clinicians at the point of care, including drug therapy recommendations. While broader than medication-specific CDS, it overlaps with Synapse Copilot Follow and MedGPT.fr as an AI-adjacent knowledge resource for prescribers.

TypeOthers
Description

Surescripts is the dominant US e-prescribing network, and Synapse Prescribe's ONC certification explicitly relies upon Surescripts software. While not a direct competitor in CDS, it is a critical infrastructure provider and adjacent ecosystem participant relevant to Synapse's US distribution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synapse Medicine

Clinical Decision Support Softwaresynapse-medicine.com

Synapse Medicine builds an AI-powered medication intelligence platform delivered via APIs and React Native components to EHR, e-prescribing, and telehealth software vendors, as well as directly to hospitals. The platform serves 400,000+ healthcare professionals and 150,000+ doctors via MedGPT.fr across France, the US, Europe, and Asia.

What Synapse Medicine does

Synapse Medicine is a French healthtech company founded in 2017 that builds an AI-powered medication intelligence platform for healthcare professionals and software vendors. Headquartered in Bordeaux with offices in Paris, New York, and coworking locations in Lacanau and Montalivet, the company develops a knowledge-graph-architecture platform that aggregates heterogeneous drug data from official sources, including the 40-year-old Thériaque certified drug database. Its product portfolio includes Synapse Database (multi-source drug information), Synapse Secure (CE Class IIb-certified prescription safety), Synapse Copilote (an AI suite with voice, clinical follow-up, and prescription optimization modules), Synapse Prescribe (ONC-certified for the US market), and sub-brands MedGPT.fr (a generative AI medical assistant used by 150,000+ doctors in France) and Goodmed (a patient-facing app).

The underlying technology combines a proprietary knowledge graph and Synapse ontology with internally developed NLP, OCR, and recommendation algorithms, and uses Mistral LLMs for generative AI features. The platform is delivered as APIs and React Native front-end components that integrate into EHR, e-prescribing, and telehealth software, with 60+ vendor integrations completed and 400,000+ healthcare professionals reached across France, the US, Europe, and Asia. Synapse Medicine holds CE Class IIb, ISO 13485, ONC Certified Health IT, and HAS LAP/LAD certifications.

Synapse Medicine operates a B2B subscription revenue model combining direct enterprise sales to hospitals and large healthcare organizations with OEM/embedded licensing of APIs and React Native components to healthcare software vendors. Pricing is quote-based and not publicly disclosed. The go-to-market motion pairs enterprise field sales (particularly for large hospital systems and EHR publishers) with an API-first, developer-friendly integration approach. The company has raised approximately €35-40M across three funding rounds (seed 2019, Series A 2020, Series B 2022 led by Korelya Capital), with investors including XAnge, BNP Paribas Développement, MACSF, and Mutuelles Impact.

Synapse Medicine firmographics

Firmographics
Name
Synapse Medicine
Legal name
Synapse Medicine
Website
https://synapse-medicine.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Synapse Medicine builds an AI-powered medication intelligence platform delivered via APIs and React Native components to EHR, e-prescribing, and telehealth software vendors, as well as directly to hospitals. The platform serves 400,000+ healthcare professionals and 150,000+ doctors via MedGPT.fr across France, the US, Europe, and Asia.
Ownership category
akta.pro rank

Synapse Medicine industry classification

Industry
Product category
Clinical Decision Support Software
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACAKAG
Specialty Pharmacy & Complex Therapy Management Platforms
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Clinical decision support
  • Medication intelligence
  • Prescription safety software
  • Healthcare API integration
  • Electronic prescribing platform

Where Synapse Medicine is headquartered

Location

Headquarters

HQ city
Bordeaux
HQ country
France
HQ region
Europe

Offices5 records

Markets served

Synapse Medicine business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. API and Component Licensing: Revenue generated from licensing clinical decision support APIs and customizable React Native components to healthcare software vendors (EHR, e-prescribing platforms). Software publishers integrate Synapse widgets and pay for usage based on API calls or component deployments.
  2. Enterprise Software Subscriptions: Direct sales to hospitals and healthcare organizations for prescription safety solutions. Complete suite of clinical decision support APIs and customizable front-end components.
  3. Synapse Database: Multi-source reliable drug database providing coverage of health products for international expansion

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise deployment with full API access and component suite

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Synapse Medicine product offering

Product offering

Core offering

Synapse Medicine develops a medication intelligence platform that provides clinical decision support APIs and React Native components for healthcare software vendors and providers. The platform aggregates official drug databases and uses AI to power prescription safety, drug interaction analysis, dosage verification, and personalized clinical recommendations. It is delivered as embeddable software integrated into EHR and e-prescribing systems, certified as a CE Class IIb medical device in Europe and ONC Certified Health IT in the US.

Product overview

Synapse Medicine offers a modular medication intelligence platform composed of three core products: Synapse Database (multi-source drug information), Synapse Secure (prescription safety with CE Class IIb medical device certification), and Synapse Copilote (AI-powered clinical decision support suite including voice assistant, prescription optimizer, and clinical follow-up tools). The platform is available as APIs and React Native components for EHR integration, serving over 400,000 healthcare professionals across France, the US, Europe, and Asia. Key sub-brands include MedGPT.fr (generative AI for 150,000+ doctors) and Goodmed (patient-facing app). The company also offers numerous clinical widgets (dosage analysis, drug interactions, adverse effects, pathology/allergy search, geriatric recommendations) and a pharmacovigilance module (Medication Shield), all integrated via a unified API architecture.

Differentiator

Problem solved

Functional benefit

Brands

  • MedGPT: Generative AI medical assistant for healthcare professionals, the first French medical AI dedicated to healthcare professionals, available at medgpt.fr
  • Goodmed

Products and services

  • Synapse Copilote

Quantifiable outcome

  • 400,000+ healthcare professionals using the platform
  • +4 more outcomes

Companies that use Synapse Medicine

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Synapse Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature8 records

Synapse Medicine partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered key partner, integration partner, core data partner, government partner, research partner and clinical partner.

  • CGMkey partnerTechnology or IntegrationIntegration of Synapse Medicine's clinical decision support into CGM's e-prescribing software for European market. CGM is a major healthcare software provider.
  • Hellocareintegration partnerTechnology or IntegrationAPI and component integration into Hellocare telehealth platform to enable safer prescribing within their solution.
  • Lifenintegration partnerTechnology or IntegrationPartnership extending interoperability to medication reconciliation and medication management on the Lifen Platform for improved patient care.
  • Thériaquecore data partnerTechnology or Integration40-year-old certified drug database, one of 5 databases approved by HAS (French health authority). Thériaque provides the foundational drug information for Synapse's platform.
  • ANSM (Agence nationale de sécurité du médicament)government partnerTechnology or IntegrationFrench medicines agency partnership for automatic annotation of adverse event reports during COVID-19 vaccination campaign. Module analyzing daily patient treatment reports.
  • Brigham and Women's Hospitalresearch partnerStrategic or Co-development PartnerHealthcare research partnership for trusted drug information access initiatives.
  • Gustave Roussyclinical partnerStrategic or Co-development PartnerMajor French cancer center partnership for medication intelligence platform deployment.
  • Harvard Universityresearch partnerStrategic or Co-development PartnerAcademic partnership for healthcare innovation research collaboration.
  • Vanderbilt Universityresearch partnerStrategic or Co-development PartnerAcademic research partnership for healthcare technology innovation.
  • Tokyo Metropolitan Governmentgovernment partnerStrategic or Co-development PartnerPartnership for drug information platform deployment in Japan, supporting international expansion.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Synapse Medicine competitors and assessment

Company assessment

Broad incumbents

  • Wolters Kluwer (Lexicomp / Medi-Span / UpToDate): Wolters Kluwer is a large incumbent in drug information and clinical decision support, with Lexicomp and Medi-Span providing the same core capabilities as Synapse Medicine (drug interaction checking, dosage analysis, monographs) sold into hospitals, EHR vendors, and pharmacies. Comparable because it competes head-to-head in medication-decision support at enterprise scale.
  • Elsevier (ClinicalKey / Gold Standard Drug Database): Elsevier's Clinical Pharmacology and Gold Standard Drug Database compete directly with Synapse Database and Synapse Secure, providing drug monographs, interaction analysis, and clinical decision support to hospitals and EHR platforms. Comparable as an established content-and-CDS vendor with broad hospital penetration.
  • Epic Systems (CDS modules): Epic's Best Care Alert and embedded CDS modules include medication interaction and dosing alerts that compete with Synapse's offering for hospitals running Epic. While Epic is primarily an EHR vendor, its native CDS capabilities are a direct substitute and a channel consideration for Synapse's OEM strategy.
  • UpToDate (Wolters Kluwer): UpToDate is a leading evidence-based clinical decision support resource used by clinicians at the point of care, including drug therapy recommendations. While broader than medication-specific CDS, it overlaps with Synapse Copilot Follow and MedGPT.fr as an AI-adjacent knowledge resource for prescribers.

Direct peers

  • First Databank (FDB): First Databank provides drug knowledge bases and clinical decision support modules embedded in EHRs and pharmacy systems, including medication screening, interaction checking, and dosing guidance - the same product surface area as Synapse Secure and Synapse Copilote. Highly comparable as a specialized CDS content and software vendor.
  • DrFirst: DrFirst delivers e-prescribing, medication management, and clinical decision support APIs to hospitals and EHR vendors, with similar OEM/embedded distribution model as Synapse Medicine. Comparable in both product scope and go-to-market approach targeting healthcare software publishers.
  • RxRevu (CoverMyMeds): RxRevu, now part of CoverMyMeds/McKesson, provides prescription decision support and real-time benefit check APIs integrated into EHR workflows - directly comparable to Synapse Prescribe and Synapse Copilote for medication decision support at the point of prescribing.
  • CGM (CompuGroup Medical): CGM is both a partner and a comparable peer: it is a leading e-prescribing and practice management software vendor in Europe that has integrated Synapse's CDS but also operates its own clinical decision capabilities. Comparable as an e-prescribing/medication software vendor with hospital and physician footprint in Europe.

Emerging players

  • HelloCare: HelloCare is a telehealth platform that has integrated Synapse Medicine's API and components for safer prescribing. While smaller and more regionally focused, it is comparable as a clinical-software customer/partnership case study in the same digital health segment.

Others

  • Surescripts: Surescripts is the dominant US e-prescribing network, and Synapse Prescribe's ONC certification explicitly relies upon Surescripts software. While not a direct competitor in CDS, it is a critical infrastructure provider and adjacent ecosystem participant relevant to Synapse's US distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Synapse Medicine social profiles

Digital presence

Synapse Medicine compliance and trust

Trust signal

Compliance4 records

Synapse Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synapse Medicine leadership team

Management profile

Number of profiles

Profiles8 records

Synapse Medicine subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Synapse Medicine funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synapse Medicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synapse Medicine

What does Synapse Medicine do?

Synapse Medicine develops a medication intelligence platform that provides clinical decision support APIs and React Native components for healthcare software vendors and providers. The platform aggregates official drug databases and uses AI to power prescription safety, drug interaction analysis, dosage verification, and personalized clinical recommendations. It is delivered as embeddable software integrated into EHR and e-prescribing systems, certified as a CE Class IIb medical device in Europe and ONC Certified Health IT in the US.

Is Synapse Medicine a public or private company?

Synapse Medicine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Synapse Medicine founded?

Synapse Medicine was founded in 2017. It employs 51 to 100 people.

Where is Synapse Medicine based?

Synapse Medicine is headquartered in Bordeaux, France, in the Europe region.

How does Synapse Medicine make money?

Three revenue lines are on record. API and Component Licensing is the primary driver. The others are enterprise Software Subscriptions and synapse Database.

Who are Synapse Medicine's main competitors?

Broad incumbents on record are Wolters Kluwer (Lexicomp / Medi-Span / UpToDate), Elsevier (ClinicalKey / Gold Standard Drug Database), Epic Systems (CDS modules) and UpToDate (Wolters Kluwer). Direct peers are First Databank (FDB), DrFirst, RxRevu (CoverMyMeds) and CGM (CompuGroup Medical). HelloCare is listed as an emerging player. Surescripts is listed as an others.

Does Synapse Medicine have an API?

Yes. Synapse Medicine offers a complete suite of clinical decision support APIs and customizable front-end components built with React Native that integrate seamlessly into EHR, e-prescribing software, or clinical workflows. The API provides drug information, clinical decision support, prescription analysis, and medication safety features. Access is via authentication at auth.us.synapse-medicine.com/realms/integrator/login-actions/authenticate?client_id=oauth2-proxy. Developer documentation is at auth.us.synapse-medicine.com/realms/integrator/login-actions/authenticate?client_id=oauth2-proxy&tab_id=rbsI3hH6xds.

What industry is Synapse Medicine in?

Synapse Medicine's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLACAKAG, Specialty Pharmacy & Complex Therapy Management Platforms. Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WikipediaDraft:Ryan SeabergRyan Seaberg, a former American football player, founded EirSystems Inc. in 2018 after playing professionally in Europe and Asia. The company's first product, PagerRx, was sold to Synapse Medicine in 2024, and EirSystems now develops an eMAR platform.GroupImpact In Action: Investing in Impact Companies whose Technology-Driven Solutions Support Human and Environmental HealthBNP Paribas has invested in multiple impact companies focused on health tech and nature tech solutions as part of its 200 million euro impact investing envelope, including Lifeaz (a French health tech startup that raised 13 million euros in February 2026 for connected defibrillators) and Mycophyto (a biotech company that raised 16 million euros in Series A funding in January 2026 to scale production of mycorrhizal-based biostimulants and biopesticides for soil regeneration). Synapse Medicine, another health tech company backed by BNP Paribas since 2018, has developed MedGPT.fr, a generative AI tool for medical professionals now used by over 150,000 doctors in France. The article positions these investments within a 'One Health' framework that recognizes the interconnection of human, animal, and environmental health.DirectIndustry e-MagazineMedGPT: France Launches a Sovereign Medical AI DirectIndustry e-MagazineSynapse Medicine launched MedGPT, a French medical AI assistant for healthcare professionals, which outperformed ChatGPT by seven points in France's national medical exams. The tool is hosted in France, uses validated French and European sources, and is available in beta for French practitioners and students.Synapse-MedicineEnhancing Patient Safety: Automating PharmacovigilanceSynapse Medicine describes its AI-driven "Medication Shield" system, which automates the coding and severity assessment of adverse drug event reports using free-text patient reports and MedDRA terminology. The company cites two publications, including one in Drug Safety, where a LightGBM model achieved an AUC of 0.97 and F-measure of 0.80. The technology won the Prix Galien France 2021 digital health award.PR NewswireSynapse Medicine and CompuGroup Medical Announce Partnership to Revolutionize Prescribing and Clinical Decision SupportSynapse Medicine and CompuGroup Medical announced a partnership to accelerate innovation in prescribing and clinical decision support. The collaboration aims to provide physicians with personalized medical recommendations and time-saving tools, including Synapse Copilot, to reduce administrative tasks. The companies seek to improve patient safety and efficiency through this collaboration.PR NewswireSynapse Medicine and CompuGroup Medical Announce Partnership to Revolutionize Prescribing and Clinical Decision SupportSynapse Medicine and CompuGroup Medical announced a strategic partnership to integrate Synapse's clinical decision support tools into CompuGroup Medical's practice management software. This collaboration aims to enhance prescribing safety and efficiency for physicians by leveraging artificial intelligence and natural language processing technologies. The integration provides personalized medical recommendations to help doctors reduce administrative burdens and improve patient care.PR NewswireSynapse Medicine Initiates Multi-Site Implementation Study with Leading U.S HospitalsSynapse Medicine has initiated a clinical implementation study with Brigham and Women's Hospital in Boston and Vanderbilt University Medical Center in Nashville to evaluate the efficacy of its AI-driven clinical decision support and medication reconciliation technology in hospital settings. The study, led by Dr. Jeffrey L. Schnipper, will measure how Synapse Medicine's point-of-care tools impact inpatient pharmacist efficiency and medication safety, with potential to reduce adverse drug events that cost U.S. healthcare an estimated $28 billion annually. The collaboration aims to demonstrate how machine learning and real-time drug knowledge can improve medication appropriateness and patient outcomes.WebrazziDijital sağlık girişimi Synapse Medicine, 40 milyon dolar yatırım aldıSynapse Medicine, a France-based digital health startup, secured a $40 million investment led by Korelya Capital to scale its operations in the US and Europe. The company utilizes AI technology to assist doctors in prescribing appropriate medications by analyzing drug safety and suitability for individual patients. This funding follows the company's goal of providing reliable medical information through its SaaS platform.FinSMEsSynapse Medicine Raises $28M in FundingSynapse Medicine raised $28M in funding led by Korelya Capital, bringing its total to $40M. The company will use the funds to accelerate its medication reconciliation platform in the US and expand its team, with CEO Dr Clement Goehrs moving to New York. The startup plans to grow its workforce to 150 staff across multiple cities.PR NewswireSynapse Medicine lève 25M€ pour aider patients et soignants à travers le monde à mieux utiliser les médicamentsSynapse Medicine, a French health tech startup specializing in AI-powered medication intelligence, announced the closing of a €25 million funding round led by Korelya Capital, with participation from historical investors XAnge, MACSF, and BNP Paribas Développement, as well as new investor Mutuelles Impact — bringing total funds raised to €35 million. The company plans to use the proceeds to accelerate global deployment of its SaaS platform across Europe, the United States, and Japan, while tripling its workforce to 150 employees across offices in Paris, Bordeaux, Berlin, London, New York, and Tokyo. Synapse Medicine, which collaborates with French university hospitals and counts institutions like ANSM and AP-HP among its clients, aims to address the global challenge of proper medication usage, with preventable adverse drug reactions causing 350,000 hospitalizations annually in the US and 150,000 in France.